Ralph Adams

USPTO Granted Patents = 39 (Patent Applications = 18)

CIPO Patents = 9 (Patent Applications = 7)

EPO Patents = 17 (Patent Applications = 25)

Average Co-Inventor Count = 4.1

ph-index = 8

Forward Citations = 168(Granted Patents)

Location History:

Surrey, GB (2013)
Berkshire, GB (2013 - 2022)
Slough, GB (2011 - 2024)

Company Filing History:

where one patent can have more than one assignee

Years Active: 2011-2025

Loading Chart...

39 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12327614 - Multi-domain proteins with increased native state colloidal stability (2025-06-10),

2. 12247068 - Anti-AP2 antibodies and antigen binding agents to treat metabolic disorders (2025-03-11),

3. 12091450 - Antibodies of the class IGG4 (2024-09-17),

4. 12054559 - Anti-IgE antibodies (2024-08-06),

5. 11999772 - Antibodies comprising a polypeptide inserted in framework 3 region (2024-06-04),

6. 11919950 - Expression vector encoding antibody molecule which binds IL-17A and IL-17F (2024-03-05),

7. 11466076 - Binding domain or antibody specific to a human serum albumin (HSA) (2022-10-11),

8. 11261242 - Anti-alpha-synuclein antibodies (2022-03-01),

9. 11214627 - Anti-IgE antibodies (2022-01-04),

10. 11091542 - Antibody molecules which bind TNF alpha (2021-08-17),

11. 11014979 - Anti-AP2 antibodies and antigen binding agents to treat metabolic disorders (2021-05-25),

12. 10562966 - Antibodies of the class IGG4 (2020-02-18),

13. 10421816 - Multivalent antibodies (2019-09-24),

14. 10407513 - Biological products (2019-09-10),

15. 10308723 - Method of treating inflammation by administering antibody molecules which bind IL-17A and IL-17F (2019-06-04),

Title: Ralph Adams - Innovator in Antibody Development

Introduction

Ralph Adams, based in Slough, GB, is a distinguished inventor with an impressive portfolio of 37 patents. His work primarily focuses on the development of innovative antibodies, addressing significant medical challenges.

Latest Patents

Among Ralph's latest innovations are two notable patents. The first patent pertains to "Antibodies of the class IGG4." This invention details an antibody comprising at least one heavy chain with a C1 domain and a hinge region. Key features include the substitution of an inter-chain cysteine at position 127 with another amino acid and the modification of amino acids in the upper hinge region to include cysteine.

The second patent, "Anti-IgE antibodies," relates to improved anti-IgE antibodies and antigen binding agents. This invention is significant for treating disorders caused by IgE, such as allergic and certain autoimmune responses. It focuses on enhanced affinity for IgE and improved interactions with the Cε2 domain of IgE, which could revolutionize treatments for IgE-mediated disorders.

Career Highlights

Ralph has made substantial contributions in the biopharmaceutical field, having worked with leading companies such as UCB Biopharma Sprl and UCB Pharma, S.A. His expertise in antibody science has positioned him as a key figure in the development of therapeutic strategies to combat IgE-related conditions.

Collaborations

Throughout his career, Ralph has collaborated with notable professionals like Andrew George Popplewell and Stephen Edward Rapecki. These collaborations have further enriched his research and development efforts, leading to significant advancements in antibody-based therapies.

Conclusion

Ralph Adams exemplifies innovation in biomedicine through his extensive patent portfolio and collaborative spirit. His contributions to antibody development not only demonstrate his prowess as an inventor but also the potential impact of his work on treating immunity-related disorders. As he continues to push the boundaries of scientific understanding, the medical community can look forward to advancements stemming from his research.

This text is generated by artificial intelligence and may not be accurate.